Akari Therapeutics, Plc (AKTX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -30.99M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 4.87M USD | Research and Development Expense |
| Selling, general and administration | 8.81M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-30.99M | (m) | (m) | $4.87M | $8.81M | (m) |
| 2026-03-31 | $-29.51M | (m) | (m) | $3.46M | $8.74M | (m) |
| 2025-12-31 | $-17.27M | (m) | (m) | $2.81M | $9.28M | (m) |
| 2025-09-30 | $-19.33M | (m) | (m) | $2.98M | $10.19M | (m) |
| 2025-06-30 | $-14.85M | (m) | (m) | $2.87M | $9.92M | (m) |
| 2025-03-31 | $-19.18M | (m) | (m) | $5.52M | $8.67M | (m) |
| 2024-12-31 | $-21.64M | (m) | (m) | $6.98M | $9.66M | (m) |
| 2024-09-30 | $-17.71M | (m) | (m) | $4.42M | $9.20M | (m) |
| 2024-06-30 | $-21.04M | (m) | (m) | $7.79M | $10.31M | (m) |
| 2024-03-31 | $-18.20M | (m) | (m) | $6.00M | $12.20M | (m) |
| 2023-12-31 | $-16.81M | (m) | (m) | $5.45M | $11.36M | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-21.24M | (m) | (m) | $7.83M | $13.41M | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-23.09M | (m) | (m) | $9.56M | $13.53M | (m) |
| 2022-06-30 | $-18.40M | (m) | (m) | $8.41M | $9.98M | (m) |
| 2021-12-31 | $-17.21M | (m) | (m) | $9.13M | $8.08M | (m) |
| 2021-06-30 | $-17.02M | (m) | (m) | $8.78M | $8.24M | (m) |
| 2020-12-31 | $-17.98M | (m) | (m) | $8.82M | $9.16M | (m) |
| 2020-09-30 | $-18.91M | (m) | (m) | (m) | $9.05M | (m) |
| 2020-06-30 | $-21.78M | (m) | (m) | $13.22M | $8.57M | (m) |
| 2020-03-31 | $-21.90M | (m) | (m) | (m) | $8.11M | (m) |
| 2019-12-31 | $-16.96M | (m) | (m) | $8.74M | $8.22M | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $-13.73M | (m) | (m) | $6.94M | $9.49M | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-19.99M | (m) | (m) | $11.80M | $10.90M | (m) |
| 2018-06-30 | $-34.44M | (m) | (m) | $19.63M | $12.11M | (m) |
| 2017-12-31 | $-37.78M | (m) | (m) | $23.29M | $11.80M | (m) |
| 2017-06-30 | $-31.51M | (m) | (m) | $20.15M | $11.36M | (m) |
| 2016-12-31 | $-27.25M | (m) | (m) | $17.31M | $9.94M | (m) |
| 2016-06-30 | $-38.99M | (m) | (m) | $10.19M | $9.52M | (m) |
| 2016-03-31 | $-32.78M | (m) | (m) | $5.74M | $7.75M | (m) |
| 2015-12-31 | $-30.58M | (m) | (m) | $5.80M | $5.50M | (m) |
| 2015-09-30 | $-35.66M | (m) | (m) | $9.75M | $6.63M | (m) |
| 2015-06-30 | $-9.76M | (m) | (m) | $5.77M | $3.99M | (m) |
| 2015-03-31 | $-10.64M | (m) | (m) | $7.17M | $3.47M | (m) |
| 2014-12-31 | $-10.18M | (m) | (m) | $6.42M | $3.76M | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-3.61M | (m) | (m) | $1.28M | $2.33M | (m) |
| 2012-12-31 | $-3.67M | (m) | (m) | $1.48M | $2.18M | (m) |
| 2011-12-31 | $-2.25M | (m) | (m) | $841.00K | $1.41M | (m) |
| 2010-12-31 | $-792.00K | (m) | (m) | $247.00K | $545.00K | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |